➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Colorcon
Baxter
Dow
Johnson and Johnson

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Patent: 10,182,984

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,182,984
Title:Targeted interferons demonstrate potent apoptotic and anti-tumor activities
Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-.alpha.) or interferon beta (IFN-.beta.).
Inventor(s): Morrison; Sherie L. (Los Angeles, CA), Huang; Tzu-Hsuan (Libertyville, IL), Xuan; Caiyun (Newton, MA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:15/359,456
Patent Claims:see list of patent claims

Details for Patent 10,182,984

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial The Regents of the University of California (Oakland, CA) 2027-09-21 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial The Regents of the University of California (Oakland, CA) 2027-09-21 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial The Regents of the University of California (Oakland, CA) 2027-09-21 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial The Regents of the University of California (Oakland, CA) 2027-09-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,182,984

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2009039409   Start Trial
United States of America 2010172868   Start Trial
United States of America 2010297076   Start Trial
United States of America 2011104112   Start Trial
United States of America 2014079668   Start Trial
United States of America 2017151342   Start Trial
United States of America 8258263   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Express Scripts
Mallinckrodt
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.